spacer
home > ict > autumn 2018 > navigating through uncharted waters
PUBLICATIONS
International Clinical Trials

Navigating Through Uncharted Waters

Gene-based therapies are members of a larger therapeutic category characterised as advanced therapy medicinal products (ATMP). Most stakeholders recognise the potential impact of new gene-based therapies: improved outcomes and quality of life for patients with some of the most complex and chronic genetic conditions, which can be presented with considerable clinical variation.

In particular, the industry witnessed several milestones in 2017, including approval by the FDA that allowed the first gene-based treatment for an inherited eye disease in the US (1). Earlier in 2017, the FDA also cleared two other gene-based treatments targeting advanced haematologic malignancies (2).

Such industry developments underscore a renewed readiness to advance gene-based clinical trials after a series of high-profile setbacks in the late1990s prompted the FDA and the EMA to develop additional guidance for clinical trials involving gene-based therapies − including oversight procedures emphasising short- and long-term patient safety. A layered and either sequential or overlapping review process includes institutional review boards, institutional biologic committees, and the National Institutes of Health assuring protocol adherence and proper handling of therapeutics.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Michael F Murphy’s professional career has spanned 30 years, and his positions emphasise the integration of medical and scientific acumen with operational excellence. He is board-certified in psychiatry, with a doctorate in pharmacology, training at Tulane University, Stanford University, and the Icahn School of Medicine at Mount Sinai, US. In 2017, he was the recipient of the Clinical Research and Excellence Lifetime Achievement Award and selected as one of the 100 Most Inspiring People in the life sciences industry. His supervisory responsibilities as Chief Medical and Scientific Officer at Worldwide Clinical Trials are international in scope.

Dr deMauri Mackie is a member of a unique fellowship programme at Worldwide Clinical Trials, which combines didactic and experiential training across R&D activities for novel chemical entities, biological products, and devices. She has a BA in biochemistry from the University of Pennsylvania, US, and a PhD in cellular and molecular medicine from Johns Hopkins University, US.

Sophie Humphrey has worked in the clinical research industry for over 10 years, five of which have been at Worldwide Clinical Trials, filling lead roles within regulatory affairs, business development, and study start-up in fast-paced CRO environments. Sophie has experience of submission management, as well as providing expertise on legislative framework, project representation, and strategy on regulatory and development activities of trials. Her regional experience extends to EU, the Middle East, Africa, and Asia-Pacific across a wide range of therapeutic indications.

Dinah Otieno has worked in global clinical study start-up and regulatory affairs for the past decade and has been the Global Start Up and Regulatory Manager at Worldwide Clinical Trials since 2016. Dinah is responsible for site regulatory compliance and drug release activities for country site activation. She has over 17 years’ experience within the academic and CRO industry, where she oversees preparation of various strategic and process improvements for streamlined working procedures in regulatory and clinical start-up submission to country-specific regulatory agencies. Dinah obtained her undergraduate degree in Psychology from the University of North Carolina at Greensboro, US.
spacer
Dr Michael F Murphy
spacer
spacer
spacer
Dr deMauri Mackie
spacer
spacer
spacer
Sophie Humphrey
spacer
spacer
spacer
Dina Otieno
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Düsseldorf/Olten, July 03, 2019 – Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine®, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinson’s disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinson’s patients greater independence in their day-today lives.
More info >>

White Papers

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

Temptime Corporation

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement